Amicus Therapeutics – A Biopharmaceutical Firm Based in New Jersey

Amicus Therapeutics is a biopharmaceutical firm based in New Jersey, America. The firm went public in 2007 under the trading name, NASDAQ (Google Finance). The establishment of Amicus Therapeutics was financed by selected capital venture firms such as Radius Venture, New Enterprise Associates, and Canaan Partners. The organization focuses on the treatment of rare and orphan diseases, more so lysosomal storage disorders. The product development of the company is primarily based on CHART (Chaperone-Advanced Replacement Therapy), as well as enzyme replacement therapies.
In 2014, Amicus Therapeutics was noted as one of the companies that have the broadest portfolio of pharmacological chaperones small molecule in the pharmaceutical industry. Moreover, Amicus Therapeutics has a robust development pipeline for the treatment of various human genetic disease. For example, Amicus Therapeutics has a lead product known as migalastat. The product is a personalized medicine that is used for treating people with Fabry disease. Amicus Therapeutics is also working in collaboration with JCR Pharmaceutical and GlaxoSmithKline to explore coformulation with the recombinant alpha-galactosidase. However, the collaboration lasted for only three years.
Amicus does not have the manufacturing capability to produce its products. It relies on contracts from other companies for the manufacturing process. However, in 2008, the company expanded its operation. Apart from the normal research site in New Jersey, Amicus Therapeutics also has another research site in San Diego. Since its establishment, Amicus has been on the good side of the business. In 2010, Amicus Therapeutics received a grant worth $500000 from Michael Joseph Fox Foundation. The grant was meant to support the research study that was being conducted by Amicus in partnership with David Geffen Medical School. The company also received another grant worth $210300 from ADDF (Alzheimer’s Drug Discovery Foundation). Amicus Therapeutics used the grant to support its pre-clinical work. Also, in 2013, Amicus was able to have the necessary intellectual property and proprietary materials for the treatment of Pompe infection.

For more information visit:

| Twitter


Business + Spirituality = Joseph Bismark

I have found this article on Come On Valerie which states that Joseph Bismark believes in adding spirituality to business. Joseph is on the way to changing lives in many different ways. He is providing spiritual change, social change, emotional change and business change. He is also looking at ways to promote physical health. All of these things are important to him if one is supposed to live a prosperous life. I hold that belief myself. I’ve also read that Bismark works in the multinational team of QI Group. He is the director of management on that team. He has started that line of work back at the end of 2008. He has been very important to the success of the business with his unique approach to dealing with people.

He is also certified in philosophy. He is a meditation trainer as well. He lived comfortably as a child until age 9 when he devoted his life to become a monk until age 17. He has gained a lot of wisdom at his time in the mountains and has been sharing his wisdom as well as putting it to work upon his return. Throughout his career, he has proven to be an exceptional leader. He has an admirable devotion to his spirituality. He is also committed to health and wellness. He doesn’t believe that one should sacrifice one aspect of his life for another. Health and wellness is very important to the life of an individual.

Joseph Bismark will continue to build his and achieve success as an individual. He will continue to inspire others as he did me. I am hoping to learn a lot from his example and maybe put it to good use in my life. He really looks for ways he could add to the life of others that he gets involved with.